Lung cancer in Berlin ' Significant changes in age structure, gender ratio and histologic subtypes from 2000 to 2008
Torsten Blum(MSB Medical School Berlin), Anita Jagota(Zentrum Überleben), Christel Lauer(Helios Klinikum Emil von Behring), Gunda Leschber, Christian Grah(Gemeinschaftskrankenhaus Havelhöhe), Wulf Pankow(German Respiratory Society), Paul Schneider(DRK Kliniken Berlin), Christian Gogoll(St. Hedwig-Krankenhaus), Stephan Eggeling(Vivantes Klinikum), Jens Neudecker(Humboldt-Universität zu Berlin), Nicolas Schoenfeld(Helios Klinikum Emil von Behring), Christian Witt(Heidelberg University), Christian Grohé(DRK Kliniken Berlin), B Schicke(Zentrum Überleben)
European Respiratory Journal
September 1, 2012
Cited by 0
Related Papers
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC
|New England Journal of Medicine|2023|605
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial
|The Lancet Respiratory Medicine|2021|523
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
|Journal of Clinical Oncology|2023|386